Galapagos News

142,85 -3,02% -4,45 €
18.10.19 15:52:49 Frankfurt | Orderbuch | Mehr Kurse »
WKN: A0EAT9
ISIN: BE0003818359
US-Symbol: GLPGF
Typ: Aktie

Galapagos News

  
11.10.19 GILEAD AND GALAPAGOS ANNOUNCE EFFICACY AND SAFETY RESULTS OF FILGOTINIB THROUGH 52 WEEKS IN FINCH 1 AND FINCH 3 STUDIES IN RHEUMATOID ARTHRITIS GlobeNewswire
07.10.19 Galapagos receives transparency notification from Wellington Management Group LLP GlobeNewswire
24.09.19 Galapagos initiates Phase 1 trial for second Toledo compound GlobeNewswire
20.09.19 Invitation to the special and extraordinary shareholders' meetings GlobeNewswire
20.09.19 Invitation to the special and extraordinary shareholders' meetings GlobeNewswire
19.09.19 Transparency notification GlobeNewswire
19.09.19 Galapagos increases share capital through warrant exercises GlobeNewswire
30.08.19 Transparency notification GlobeNewswire
28.08.19 Transparency notification – Gilead holds 22% of Galapagos shares GlobeNewswire
23.08.19 Gilead and Galapagos Complete Closing of Their Transformative Research and Development Collaboration GlobeNewswire
15.08.19 EUROPEAN MEDICINES AGENCY VALIDATES MARKETING APPLICATION FOR FILGOTINIB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS GlobeNewswire
25.07.19 Strong clinical progress in H1 and transformative collaboration with Gilead announced GlobeNewswire
18.07.19 Transparency notification GlobeNewswire
15.07.19 US-​Biotechkonzern Gilead baut Anteil an Galapagos aus - Zugriff auf Portfolio dpa-AFX
15.07.19 Hammer‑News: Gilead mit Milliarden‑Deal – ist die Aktie jetzt ein Kauf? Der Aktionär
14.07.19 GILEAD AND GALAPAGOS ENTER INTO TRANSFORMATIVE RESEARCH AND DEVELOPMENT COLLABORATION GlobeNewswire
02.07.19 GILEAD ANNOUNCES INTENT TO SUBMIT NEW DRUG APPLICATION FOR FILGOTINIB TO U.S. FOOD AND DRUG ADMINISTRATION THIS YEAR GlobeNewswire
20.06.19 Galapagos increases share capital through warrant exercises GlobeNewswire
17.06.19 Transparency notification GlobeNewswire
11.06.19 Servier and Galapagos complete enrollment of global ROCCELLA Phase 2 clinical trial with GLPG1972/S201086 in knee osteoarthritis patients GlobeNewswire
29.05.19 GILEAD AND GALAPAGOS TO PRESENT LATEST DATA ON FILGOTINIB AT THE ANNUAL EUROPEAN CONGRESS OF RHEUMATOLOGY (EULAR 2019) GlobeNewswire
25.04.19 Galapagos reports on historic first quarter 2019 GlobeNewswire
24.04.19 Stark: Morphosys legt Grundstein für nächsten Erfolg - Aktie nimmt Fahrt auf Der Aktionär
23.04.19 Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis patients GlobeNewswire
10.04.19 Galapagos creates new warrant plans GlobeNewswire
29.03.19 Publication of the annual report and invitation to the annual shareholders' meeting GlobeNewswire
28.03.19 GILEAD AND GALAPAGOS REPORT UPDATED SAFETY INFORMATION FOR FILGOTINIB IN RHEUMATOID ARTHRITIS (RA) GlobeNewswire
28.03.19 GILEAD AND GALAPAGOS REPORT UPDATED SAFETY INFORMATION FOR FILGOTINIB IN RHEUMATOID ARTHRITIS (RA) GlobeNewswire
28.03.19 GILEAD AND GALAPAGOS ANNOUNCE FILGOTINIB MEETS PRIMARY ENDPOINT IN THE PHASE 3 FINCH 3 STUDY IN METHOTREXATE-NAÏVE RHEUMATOID ARTHRITIS PATIENTS GlobeNewswire
28.03.19 GILEAD AND GALAPAGOS ANNOUNCE FILGOTINIB MEETS PRIMARY AND KEY SECONDARY ENDPOINTS IN THE PHASE 3 FINCH 1 RHEUMATOID ARTHRITIS STUDY GlobeNewswire
20.03.19 Galapagos increases share capital through warrant exercises GlobeNewswire
21.02.19 Firmly on our way to becoming a fully integrated biopharma company GlobeNewswire
07.02.19 Evotec gelingt neuer Deal - kommt nun das Kaufsignal? Der Aktionär
07.02.19 Evotec and Galapagos enter into collaboration in the field of fibrosis GlobeNewswire
21.01.19 Galapagos Aktie 2019 Finanztrends
08.01.19 Sands Capital reports 5.7% holding in Galapagos GlobeNewswire
07.01.19 Galapagos starts first Phase 1 trial with Toledo compound GlobeNewswire
06.01.19 Galapagos initiates NOVESA Phase 2a trial in patients with systemic sclerosis GlobeNewswire
04.01.19 Fibrocor and Galapagos sign partnership in fibrosis GlobeNewswire
21.12.18 Galapagos to Present at 37th Annual J.P. Morgan Healthcare Conference GlobeNewswire
17.12.18 Galapagos reports initiation of ISABELA Phase 3 program with GLPG1690 in patients with Idiopathic Pulmonary Fibrosis (IPF) GlobeNewswire
27.11.18 Galapagos receives Fast Track designation from FDA for GLPG1972/S201086 in osteoarthritis GlobeNewswire
26.11.18 Transparency notification GlobeNewswire
23.11.18 Galapagos increases share capital through warrant exercises GlobeNewswire
31.10.18 Galapagos reports initiation of PINTA Phase 2 trial with GLPG1205 in patients with Idiopathic Pulmonary Fibrosis (IPF) GlobeNewswire
24.10.18 Galapagos and AbbVie restructure CF collaboration GlobeNewswire
24.10.18 Topline interim results of FALCON trial Part 1 in CF GlobeNewswire
24.10.18 Hallmark third quarter 2018 and Annual R&D Update at Galapagos GlobeNewswire
22.10.18 POSITIVE TRIAL RESULTS WITH FILGOTINIB IN PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS BOTH PUBLISHED IN THE LANCET GlobeNewswire
21.10.18 PHASE 3 DATA ON FILGOTINIB IN BIOLOGIC-​EXPERIENCED RHEUMATOID ARTHRITIS TO BE PRESENTED AT 2018 ACR/ARHP ANNUAL MEETING GlobeNewswire

Newssuche

  

Videos

  
18.10.19 -2,64%
Börsenpunk: Langweilig, aber geil! A2 Milk, Helen of Troy, Coca-Cola, Logitech ins Depot / Hot Stock Fingerprint Cards